Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACA | Q13085 | 12/20 | 0.51 |
| ▸ | ACACB | O00763 | 15/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968779 | 0.93 | ACACB (0.49) | ACACAACACBMAPTGPR119SMN1; SMN2 | |
| SCHEMBL15968571 | 0.93 | ACACA (0.59) | ACACAACACB | |
| SCHEMBL15968471 | 0.89 | ACACB (0.44) | ACACAACACB | |
| SCHEMBL15968565 | 0.88 | ACACB (0.43) | ACACAACACBMAPTPOLBSMN1; SMN2 | |
| SCHEMBL15969125 | 0.88 | ACACB (0.43) | ACACAACACB | |
| SCHEMBL15967988 | 0.88 | ACACB (0.44) | ACACAACACB | |
| SCHEMBL15968509 | 0.88 | ACACB (0.44) | ACACAACACBGPR119 | |
| SCHEMBL15968829 | 0.86 | ACACB (0.42) | ACACAACACB | |
| SCHEMBL15968567 | 0.86 | ACACB (0.42) | ACACAACACB | |
| SCHEMBL15968632 | 0.86 | ACACB (0.57) | ACACAACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | ACACA 670/4885ACACB 1112/4885MAPT 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.